MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-02-2023
Surface Oncology ROCE Ratio 2011-2026 | SURF
Annual ROCE Ratio Surface Oncology
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -66.24 | -63.93 | 39.54 | -51.03 | -6.23 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 39.54 | -66.24 | -29.58 |
Quarterly ROCE Ratio Surface Oncology
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -118.66 | -86.11 | -35.23 | -50.09 | -44.65 | -37.62 | -36.56 | 7.08 | 12.72 | 15.93 | 39.54 | -32.92 | -54.68 | -78.01 | -101.24 | -77.84 | -64.39 | -47.84 | -8.9 | 21.24 | 59.97 | 85.79 | 68.32 | 43.61 | 22.41 | 12.71 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 85.79 | -118.66 | -18.67 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Regeneron Pharmaceuticals
REGN
|
11.45 | $ 742.1 | -1.93 % | $ 77.6 B |  USA |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
AbbVie
ABBV
|
-461.01 | $ 211.9 | 0.37 % | $ 375 B | USA |
 |
Replimune Group
REPL
|
-62.91 | $ 7.26 | -3.71 % | $ 585 M | USA |
 |
AbCellera Biologics
ABCL
|
-16.8 | $ 3.28 | -2.24 % | $ 980 M |  Canada |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-28.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Rigel Pharmaceuticals
RIGL
|
32.05 | $ 26.28 | -0.34 % | $ 473 M | USA |
 |
Aileron Therapeutics
ALRN
|
-299.27 | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-92.73 | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-403.4 | - | -52.27 % | $ 4.45 M | USA |
 |
Avidity Biosciences
RNA
|
-44.18 | $ 13.07 | -0.23 % | $ 1.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Rhythm Pharmaceuticals
RYTM
|
-138.07 | $ 77.56 | -5.31 % | $ 5.04 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-30.68 | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-26.11 | $ 12.27 | -12.11 % | $ 1.86 B | USA |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
SIGA Technologies
SIGA
|
11.92 | $ 5.36 | 7.96 % | $ 383 M | USA |
 |
Silence Therapeutics plc
SLN
|
-59.35 | $ 4.92 | -7.34 % | $ 622 M | Britain |
 |
SELLAS Life Sciences Group
SLS
|
-39.9 | $ 4.47 | -9.69 % | $ 487 M | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-212.83 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-45.41 | - | - | $ 3.74 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-66.51 | $ 1.08 | -1.38 % | $ 22.2 M | Israel |
 |
Enochian Biosciences
ENOB
|
903.05 | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Summit Therapeutics
SMMT
|
-56.92 | $ 16.59 | -3.88 % | $ 12.4 B | Britain |
 |
Spruce Biosciences
SPRB
|
-85.88 | $ 62.07 | -10.19 % | $ 47.6 M | USA |